|Founded||2006 in Norwood, New Jersey|
|Hayley Dinerman (Co-founder & Executive Director)|
Board of Trustees
Tim Pettee (Board Chair)
Jennifer K. Sweetwood
Eric P. Winer, MD
Scientific Advisory Board
Lisa A. Carey, MD
Susan M. Domchek, MD
Lisa A. Newman, MD
George W. Sledge, Jr., MD
Eric P. Winer, MD
The Triple Negative Breast Cancer Foundation ("TNBC Foundation" or "TNBCF") is a nonprofit organization dedicated to raising awareness of triple-negative breast cancer. The foundation supports scientists and researchers in their efforts to determine the definitive causes of triple-negative breast cancer so that effective detection, diagnosis, prevention, and treatment can be pursued and achieved.
Since its inception in 2006, TNBCF has raised over $2 million to further this mission.
TNBC Foundation was founded in 2006 in honor of Nancy Block-Zenna, who, at age 35, was diagnosed with triple-negative breast cancer. In response to her diagnosis, her close friends launched the TNBC Foundation to raise awareness and support research for this particular type of breast cancer. 1⁄2 years after her diagnosis.Block-Zenna died of the disease in 2007, 2
On December 11, 2007, the TNBC Foundation and Susan G. Komen for the Cure convened one of the first "think tanks" dedicated specifically to triple-negative breast cancer. The meeting was held prior to the opening of the annual San Antonio Breast Cancer Symposium.
Thirty researchers, from leading cancer institutions in North America and Europe, were invited to share information on the latest science, to discuss potential research collaborations and develop a scientific agenda for future research and clinical trials to find effective treatment for women with this subtype of breast cancer. The meeting also marked the first joint effort between TNBCF and Susan G. Komen for the Cure to share resources to accelerate research and progress for women who are not benefiting from recent advances in breast cancer research.
The goal of the meeting was to create the first comprehensive publication and white-paper summarizing the "state of the science" with input and authorship from leading researchers from around the world who have been dedicated specifically to this subtype of the disease. The publication will also include a roadmap and recommendations for planning, funding and designing the next level of research with the goal of identifying effective, tailored therapies for these women, thereby further reducing the rates of breast cancer mortality around the world.
Co-chairing the symposium were Allison Axenrod, executive director of TNBCF, and Hayley Dinerman, TNBCF's director of operations. The program was planned by TNBC's medical advisory board, which includes Dr. Winer as well as Lisa A. Carey, medical director of the University of North Carolina Lineberger Comprehensive Cancer Center, and George W. Sledge, Jr., professor of Medicine and Pathology and co-chair of the Breast Cancer Program at the Indiana University School of Medicine.
TNBC has convened the Symposium each year since 2007. In 2010, over 30 researchers and scientists attended the Symposium, which was again co-sponsored by Susan G. Komen for the Cure and the Breast Cancer Research Foundation (BCRF). That year, the TNBCF awarded its first independent grants to two researchers who were doing research in the area of triple-negative breast cancer.
In 2008, the Triple Negative Breast Cancer Foundation co-funded a research grant with the Susan G. Komen for the Cure Foundation. TNBCF's initial $500,000 contribution marks the first time a nonprofit partner has co-funded one of Komen's "Promise Grants". Worth $7.5 million over five years, Promise Grants are designed to bring clinical researchers and basic scientists together to deliver new treatments for patients as quickly as possible. The Promise Grant was awarded to Dr. Andreas Forero of the University of Alabama, Birmingham Comprehensive Cancer Center. Forero and his team are researching a new targeted therapy for triple-negative breast cancer.
Inflammatory breast cancer (IBC) is one of the most aggressive forms of breast cancer. It can occur at any age. It is referred to as "inflammatory" due to its frequent presentation with symptoms resembling a skin inflammation, such as erysipelas.
The Susan G. Komen 3-Day, frequently referred to as the 3-Day, is a 60-mile walk to raise funds for Susan G. Komen for the Cure and promote awareness to fight breast cancer. Individual participants must raise at least $2,300 to walk 60 miles (96 km) over a three-day weekend.
Susan G. Komen is a breast cancer organization in the United States.
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 42,000 members in over 120 countries. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Nancy Goodman Brinker is the founder of The Promise Fund and Susan G. Komen, an organization named after her only sister, Susan, who died from breast cancer in 1980 at age 36. Brinker was also United States Ambassador to Hungary from 2001 to 2003 and Chief of Protocol of the United States from 2007 to the end of the George W. Bush administration. Brinker, a breast cancer survivor, uses her experience to heighten understanding of the disease. She speaks publicly on the importance of patient's rights and medical advancements in breast cancer research and treatment. She is currently serving as the World Health Organization's Goodwill Ambassador for Cancer Control. Brinker is the author of the New York Times bestselling book Promise Me - How a Sister's Love Launched the Global Movement to End Breast Cancer, released on September 14, 2010.
The Komen Brinker Award for Scientific Distinction was established by Susan G. Komen for the Cure in 1992 to recognize leading scientists for their significant work in advancing research concepts or clinical application in the fields of breast cancer research, screening or treatment.
Breast Cancer Awareness Month (BCAM), also referred to in the United States as National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and to raise funds for research into its cause, prevention, diagnosis, treatment and cure.
Triple-negative breast cancer is any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and HER2/neu. This makes it more difficult to treat since most hormone therapies target one of the three receptors, so triple-negative cancers often require combination therapies. Triple negative is sometimes used as a surrogate term for basal-like; however, more detailed classification may provide better guidance for treatment and better estimates for prognosis.
Living Beyond Breast Cancer (LBBC), is a national 501(c)(3) nonprofit organization headquartered in Bala Cynwyd, just outside Philadelphia, Pennsylvania in the United States. LBBC works with women who have been diagnosed with breast cancer and their caregivers throughout their experience of diagnosis, treatment and recovery. Their goal to be a "high-touch organization" that provides people with information and support of relevance to their personal experience of breast cancer. The organization supports studies of health care that are sensitive to issues of ethnicity, age, sexual orientation, and diagnosis.
Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.
Dennis Joseph Slamon, is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25-33% of breast cancer patients and the resulting treatment trastuzumab.
The King Hussein Cancer Center (KHCC), is a medical center in Amman, Jordan. It treats both adult and pediatric patients. KHCC treats over 3500 new cancer patients every year from Jordan and the region.
Team Heather is a fundraising group in the Susan G. Komen for the Cure Global Race for the Cure in Washington, D.C., which has raised over $403,000, since June, 2001, for Susan G. Komen for the Cure and breast cancer research, education, screening, and treatment. Team Heather was formed in 2001 to support 25-year-old Heather Gardner (Starcher) (1976–2002), as she began her fight against breast cancer – a fight that ended on September 29, 2002.
Breast cancer awareness is an effort to raise awareness and reduce the stigma of breast cancer through education on symptoms and treatment. Supporters hope that greater knowledge will lead to earlier detection of breast cancer, which is associated with higher long-term survival rates, and that money raised for breast cancer will produce a reliable, permanent cure.
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He will be the director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022. From 1997-2021, he was the Chief of the Breast Oncology Program at Dana-Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, most recently as Chief of Clinical Development. He has been the Thompson Chair in Breast Cancer Research and a Professor of Medicine at Harvard Medical School. He is currently the president-elect of the American Society of Clinical Oncology. His career has been focused on breast cancer treatment and research.
Pinkwashing is a form of cause marketing that uses a range of pink ribbon logos, displayed on various products. The Pink ribbon logo symbolizes support for breast cancer-related charities or foundations.
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
Elisa Rush Port FACS is Associate Professor of Surgery at the Icahn School of Medicine at Mount Sinai Hospital, as well as cofounder and director of the Dubin Breast Center at the Tisch Cancer Institute at Mount Sinai Health System, since 2010. She has received four research grants, has served as an investigator or co-investigator on 15 clinical trials, published 44 peer-reviewed articles, and published a total of 12 book chapters and books. She has specialized in sentinel-node biopsy, a diagnostic method that determines cancer stages based on spread to regional lymph nodes, nipple sparing mastectomy, and the use of MRI for breast cancer.
Debra Auguste is an American chemical engineer and professor at Northeastern University in the Department of Chemical Engineering. Auguste is dedicated to developing treatments for triple negative breast cancer, one of the most aggressive and fatal cancers that disproportionately affects African American women. Her lab characterizes biomarkers of triple negative breast cancer and develops novel biocompatible therapeutic technologies to target and destroy metastatic cancer cells. Auguste received the 2012 Presidential Early Career Award for Scientists and Engineers and in 2010 was named in the 50 Most Influential African-Americans in Technology. In 2020, Auguste became an Elected Fellow of the American Institute for Medical and Biological Engineering.
Katherine A. Hoadley is an American breast cancer researcher. As of 2017, she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches.